Lokelma is a medication approved for the treatment of hyperkalemia [1]. It works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream [2].
How does Lokelma work to lower potassium levels?
Lokelma, with the active ingredient sodium zirconium cyclosilicate, functions as an ion exchanger. Once ingested, it selectively binds to potassium ions in the stomach and intestines [2][3]. This binding prevents the potassium from being absorbed into the body, effectively removing it through the stool [2]. The drug is designed to be effective across a wide range of gastrointestinal pH levels and has a high affinity for potassium compared to other cations [3].
What is hyperkalemia and why is it a concern?
Hyperkalemia is a condition characterized by abnormally high levels of potassium in the blood [1]. Potassium is an essential electrolyte for nerve and muscle function, including the heart [4]. Severe hyperkalemia can lead to life-threatening complications such as cardiac arrhythmias and cardiac arrest [1][4]. It is often associated with chronic kidney disease, heart failure, and the use of certain medications like ACE inhibitors and potassium-sparing diuretics [1].
When might a doctor prescribe Lokelma?
Doctors prescribe Lokelma for patients with hyperkalemia who require chronic potassium lowering therapy [1]. It is used to reduce and maintain serum potassium levels in adults [2].
How is Lokelma administered?
Lokelma is taken orally as a powder mixed with water [2]. Dosing is individualized based on the patient's potassium levels and treatment goals [1].
Are there alternatives to Lokelma for managing hyperkalemia?
Other medications used to treat hyperkalemia include potassium binders like patiromer (Veltassa) and sodium polystyrene sulfonate (Kayexalate, Kionex) [5]. Dietary restrictions and discontinuation or dose adjustment of medications that elevate potassium are also important management strategies [4].
What is the patent status for Lokelma?
Information regarding the specific patent expiration dates for Lokelma is available on DrugPatentWatch.com [6]. Patents provide market exclusivity for a drug.
Are there any drugs similar to Lokelma?
Patiromer is another potassium binder approved for hyperkalemia that works through a similar mechanism of binding potassium in the GI tract [5].
What are the potential side effects of Lokelma?
Common side effects associated with Lokelma include edema (swelling), hypokalemia (low potassium), constipation, and diarrhea [2].
How does Lokelma compare to other potassium binders?
Lokelma and patiromer are both potassium binders that work in the gastrointestinal tract. They differ in their chemical composition and binding characteristics. Lokelma binds potassium irreversibly, while patiromer's binding is reversible [3][5]. Clinical studies have evaluated the efficacy and safety of these agents in managing hyperkalemia [5].
What is the cost of Lokelma?
Pricing information for Lokelma can vary based on insurance coverage, pharmacy, and location.
Who manufactures Lokelma?
Lokelma is manufactured by AstraZeneca [2].
Where can I find more information on Lokelma and hyperkalemia?
Detailed information, including clinical trial data, drug interactions, and patient information, can be found on the manufacturer's website and resources like DrugPatentWatch.com [6].
What is the regulatory status of Lokelma?
Lokelma has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of hyperkalemia [1].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/lokelma-sodium-zirconium-cyclosilicate-drug-safety-communication
[2] https://www.drugpatentwatch.com/drug/lokelma
[3] https://www.drugpatentwatch.com/mechanism-of-action/sodium-zirconium-cyclosilicate
[4] https://www.niddk.nih.gov/health-information/kidney-disease/hyperkalemia
[5] https://www.drugpatentwatch.com/drug/velassa
[6] https://www.drugpatentwatch.com/